AUDIT OF PARACETAMOL PRESCRIPTIONS IN PAEDIATRIC SURGICAL PATIENTS

Rowena McArtney1, Angharad Atkinson1

  • 1Cardiff and Vale UHB.

Insights

This audit found poor adherence to guidelines for prescribing paracetamol (acetaminophen) to overweight and obese children, risking overdosing. Updated guidelines now recommend dosing based on lean body mass and reduced maximum daily doses.

Area of Science:

  • Pediatric Surgery
  • Pharmacology
  • Clinical Audit

Background:

  • Local guidelines (2012) recommended ideal body weight (IBW) for paracetamol dosing in overweight/obese children to prevent overdosing.
  • Overweight and obese children are at increased risk of paracetamol toxicity if doses are based on actual body weight.
  • BNF for Children (BNFC) indicates severe toxicity with doses as low as 75 mg/kg/24h.

Purpose of the Study:

  • To audit compliance with local guidelines for peri-operative paracetamol dosing in pediatric surgical patients.
  • To assess the accuracy of paracetamol dosing in overweight and obese children.
  • To identify potential risks of inadvertent overdosing and prolonged IV use.

Main Methods:

  • An audit of 100 inpatient and 35 discharge paracetamol prescriptions for pediatric surgical patients over 10 weeks.
  • Patients were classified as overweight or obese using UK growth charts.
  • Prescriptions were analyzed for weight documentation, dosing based on IBW, route of administration, and IV to oral switch compliance.

Main Results:

  • Weight documented for 84% inpatient, 94% discharge prescriptions; height was not documented.
  • Doses for overweight/obese patients ranged from 13-33 mg/kg/dose, with some exceeding recommended IBW calculations.
  • 20 of 52 patients on IV paracetamol were not reviewed at 48 hours for oral switch, with only 3 appropriate prolonged IV prescriptions.

Conclusions:

  • Inadequate compliance with prescribing guidelines poses a risk of inappropriate paracetamol dosing in overweight and obese children.
  • Unnecessarily prolonged IV paracetamol use was observed.
  • Local guidelines were updated in 2015 to reflect lean body mass dosing and a reduced maximum daily dose (75 mg/kg/day); prescriber education is needed.
Abstract

Keywords:
AbstractOral

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
636
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
53
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
682